AI assistant
Sending…
MYRIAD GENETICS INC — Director's Dealing 2025
Jun 2, 2025
32566_dirs_2025-06-02_833988ec-5150-4c3c-9ece-6e8045387a6c.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: MYRIAD GENETICS INC (MYGN)
CIK: 0000899923
Period of Report: 2025-05-31
Reporting Person: Raha Samraat S. (Director, President and CEO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-05-31 | Common Stock | A | 1498 | $3.562 | Acquired | 482738 | Direct |
Footnotes
F1: These shares were acquired under the Myriad Genetics, Inc. Amended and Restated 2012 Employee Stock Purchase Plan, in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).
More from MYRIAD GENETICS INC
Declaration of Voting Results & Voting Rights Announcements
2026
Jun 4
Regulatory Filings
2026
Jun 4
Share Issue/Capital Change
2026
Jun 4
Interim / Quarterly Report
2026
May 6
Report Publication Announcement
2026
May 5
Annual Report
2026
Apr 14
Proxy Solicitation & Information Statement
2026
Apr 14
Proxy Solicitation & Information Statement
2026
Apr 14
Major Shareholding Notification
2026
Apr 7
Major Shareholding Notification
2026
Mar 27